Unexpectedly strong US sales of an off-patent beta-blocker, together with sales of a new pandemic flu vaccine, drove up revenue at AstraZeneca Plc by 10% in the third quarter. For 2009, the company sees sales growth in the mid-to-high single digits.
Unexpectedly strong US sales of an off-patent beta-blocker, together with sales of a new pandemic flu vaccine, drove up revenue at AstraZeneca Plc by 10% in the third quarter. For 2009, the company sees sales growth in the mid-to-high single digits.